Multiple secondary data analyses of TORDIA have identified important predictors of treatment response and relapse .
To up date a comparative effectiveness review ( 1980–2011 ) of treatments for adolescents whose depressive episode or disorder ( MDE/MDD ) did not respond to one or more trials of SSRI antidepressants .
Fluoxetine 40-60 mg versus fluoxetine 20 mg in the treatment of children and adolescents with a less-than-complete response to nine-week treatment with fluoxetine 10-20 mg: a pilot study.
OBJECTIVE The aim of this study was to compare fluoxetine dosage titration to 40 - 60 mg/day with fixed fluoxetine 20-mg/day treatment for an additional 10 weeks in pediatric out patients with major depressive disorder ( MDD ) who had not met protocol -defined response criteria after 9-week acute fluoxetine treatment . METHODS Patients unresponsive ( less than or equal to 30 % decrease in Children 's Depression Rating Scale-Revised [ CDRS-R ] score ) after 9-week fluoxetine treatment were r and omly reassigned to continue at 20 mg/day or to increase to 40 mg/day . After 4 weeks , patients unresponsive to 40 mg/day could receive 60 mg/day . RESULTS Twenty-nine ( 29 ) patients , 9 - 17 years of age , received fluoxetine 40 - 60 mg/day ( n = 14 ) or 20 mg/day ( n = 15 ) . At the conclusion of this study phase , 10 patients ( 71 % ) on 40 - 60 mg/day met the response criteria , versus 5 patients ( 36 % ) on 20 mg/day ( p = 0.128 ) . Mean CDRS-R scores improved in both treatment groups ( fluoxetine 40 - 60 mg/day , -9.4 ; fluoxetine 20 mg/day , -1.5 ; p = 0.099 ) . Adverse events were similar in both groups . However , this study phase was statistically underpowered for detecting differences between treatment groups . CONCLUSION More than two thirds of patients whose dosage was increased responded within 10 weeks , suggesting dose escalation may benefit some patients . Approximately one third of patients unresponsive to initial treatment with fluoxetine 20 mg responded to this fixed dosage within another 10 weeks . Fluoxetine 20 - 60 mg/day was well tolerated
Multiple secondary data analyses of TORDIA have identified important predictors of treatment response and relapse .
To up date a comparative effectiveness review ( 1980–2011 ) of treatments for adolescents whose depressive episode or disorder ( MDE/MDD ) did not respond to one or more trials of SSRI antidepressants .